C. Pelligra

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States

C. Pelligra, Kejal Parikh, Shien Guo et al. · Clinical Therapeutics · 2017 · 46 citations

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for <i>F508del-CFTR</i> treated with lumacaftor/ivacaftor

Jaime Rubin, Lasair O’Callaghan, C. Pelligra et al. · Therapeutic Advances in Respiratory Disease · 2019 · 29 citations · Full text

Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma

Saad Z. Usmani, Jamie Cavenagh, Andrew R. Belch et al. · Journal of Medical Economics · 2015 · 27 citations

Modeling economic implications of alternative treatment strategies for acute bacterial skin and skin structure infections

Nikhil Revankar, Alexandra Ward, C. Pelligra et al. · Journal of Medical Economics · 2014 · 20 citations

Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes

Valeria Santini, Aristoteles Giagounidis, C. Pelligra et al. · Clinical Lymphoma Myeloma & Leukemia · 2022 · 14 citations · Full text